Skip to main content

AbbVie vs Amgen: Strategic Comparison

Direct Answer

AbbVie is the bigger company by revenue, but Amgen earned more profit in 2025. AbbVie reported $61.2 billion of revenue against Amgen's $36.8 billion, while Amgen's net income was $7.7 billion, about 1.8 times AbbVie's $4.2 billion. AbbVie was worth about twice as much on September 29, 2026: about $465.3 billion against $229.0 billion.

AbbVie and Amgen represent two premier American biotechnology and pharmaceutical corporations, each demonstrating deep specialization in biologic manufacturing, targeted oncology therapeutics, and severe autoimmune disorder interventions. AbbVie Inc., spun off from Abbott Laboratories in 2013, generated $54.3 billion in revenue in 2023, leading global commercialization in immunology (Skyrizi, Rinvoq, Humira), hematologic oncology (Venclexta, Imbruvica), neuroscience (Vraylar, Qulipta), and medical aesthetics (Botox, Juvederm). Amgen Inc., founded in Thousand Oaks, California, in 1980 as one of the founding pioneers of recombinant DNA biotechnology, generated $28.2 billion in 2023 and over $33.9 billion in 2024, anchored by longstanding biologics like Enbrel, Prolia, Xgeva, and Repatha alongside its $27.8 billion acquisition of Horizon Therapeutics. While AbbVie commands unmatched scale in specialty oral and biologic immunology, Amgen leverages deep heritage in protein engineering, biosimilars, and rare disease therapies.

Editorial research by Swet Parvadiya. Figures keep each company's fiscal year; amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Sources are listed below.

Share

Key Differences at a Glance

FieldAbbVie Inc.Amgen Inc.
Latest annual revenue$61.2B (FY2025)$36.8B (FY2025)
Founded20131980
Employees57,00031,500
Market Cap$465.8B$228.2B
HeadquartersUnited StatesUnited States
Revenue / Employee$1.07M / employee$1.17M / employee
Valuation Multiple7.6x P/S6.2x P/S

Strategic Positioning

Business model and competitive context from the cited profiles

AbbVie Inc. Strategic Vector

FY2025 Revenue Baseline

AbbVie's corporate roadmap focuses on expanding Skyrizi and Rinvoq into additional autoimmune indications while aggressively replenishing its oncology and neuroscience pipelines through targeted mergers and acquisitions. Led by Chief Executive Officer Robert Michael, AbbVie completed the acquisitions of ImmunoGen for ten billion dollars (adding Elahere, a pioneering antibody-drug conjugate for folate receptor alpha-positive platinum-resistant ovarian cancer) and Cerevel Therapeutics for nearly nine billion dollars (adding emraclidine for schizophrenia and tavapadon for Parkinson's disease). In neuroscience, AbbVie continues to expand Botox Therapeutic and oral CGRP antagonists (Qulipta, Ubrelvy) for migraine management. By pairing cash flow from aesthetics and immunology with next-generation antibody-drug conjugates (ADCs), AbbVie has established a sustainable post-Humira growth trajectory.

Productivity: $1.07M / employee

Amgen Inc. Strategic Vector

FY2025 Revenue Baseline

Amgen Inc.'s long-term commercial strategy prioritizes scaling high-margin growth vectors while actively mitigating structural industry risks. In terms of growth initiatives, management is allocating capital toward obesity drug market via maritide, where mariTide (maridebart cafraglutide) is in six Phase 3 MARITIME studies covering chronic weight management with and without Type 2 diabetes, cardiovascular outcomes, heart failure and obstructive sleep apnea. Concurrently, the organization focuses on navigating market pressures around medicare drug price negotiation under the inflation reduction act, addressing environments where the Inflation Reduction Act's Medicare negotiation provisions represent a structural threat to Amgen's long-term pricing power. By maintaining disciplined capital allocation and operational rigor, Amgen Inc. aims to protect its unit economics and preserve its economic moat across changing market cycles.

Productivity: $1.17M / employee
Comparative Divergence: The commercial competition between AbbVie and Amgen illustrates the strategic response to biologic patent cliffs and the rise of biosimilar competition. Amgen developed Amjevita, the very first biosimilar to AbbVie's Humira, launching it in the United States in early 2023. AbbVie countered by orchestrating an industry-leading therapeutic transition to its next-generation immunology assets Skyrizi (IL-23 inhibitor) and Rinvoq (JAK inhibitor), which have demonstrated superior clinical efficacy and rapidly captured market share in psoriasis, Crohn's disease, and rheumatoid arthritis. Amgen, meanwhile, diversified away from mature legacy biologics like Enbrel and Neulasta by completing the mega-acquisition of Horizon Therapeutics, bringing rare disease blockbusters Tepezza (thyroid eye disease) and Krystexxa (refractory gout) into its portfolio. Furthermore, Amgen is advancing MariTide, a monthly injectable antibody-peptide conjugate for obesity that offers competitive differentiation against Eli Lilly and Novo Nordisk. The ongoing evolution of biologic drug manufacturing also highlights corporate differences: Amgen has invested over $1 billion in state-of-the-art flexible biomanufacturing facilities utilizing modular single-use bioreactors in Ohio and North Carolina, reducing facility construction costs and carbon emissions. AbbVie maintains massive global biologics manufacturing capacity in Ireland, Puerto Rico, and Illinois, capable of supplying complex monoclonal antibodies to millions of autoimmune patients globally. In cardiovascular medicine, Amgen's PCSK9 inhibitor Repatha continues to expand statin-intolerant LDL-lowering market share, while AbbVie develops novel oral targeted therapies across systemic lupus erythematosus and alopecia areata.

AbbVie vs Amgen Market Share

AbbVie Inc. market share
AbbVie does not report company-wide market share. In FY2025 it reported $30.406 billion of immunology revenue, $10.767 billion of neuroscience revenue, $6.655 billion of oncology revenue, and $4.860 billion of aesthetics revenue.
Amgen Inc. market share
Amgen does not report market share. What it does report is scale: US$35.15 billion of product sales in fiscal 2025, 14 products above US$1 billion and 18 at record annual sales, with 73% of product sales in the United States. The largest brands were Prolia at US$4.41 billion, Repatha at US$3.02 billion, Otezla at US$2.27 billion, Enbrel at US$2.23 billion, Evenity at US$2.10 billion and XGEVA at US$2.08 billion. In denosumab and PCSK9 inhibition it holds a leading position; in inflammation and obesity it is a challenger.

Quick Stats Comparison

MetricAbbVie Inc.Amgen Inc.
Revenue$61.2B (FY2025)$36.8B (FY2025)
Founded20131980
HeadquartersNorth Chicago, IllinoisThousand Oaks, California
Market Cap$465.8B$228.2B
Employees57,00031,500
Revenue / Employee$1.07M / employee$1.17M / employee
Valuation Multiple7.6x P/S6.2x P/S

AbbVie Revenue vs Amgen Revenue — Year by Year

YearAbbVie Inc.Amgen Inc.Higher reported revenue
2025$61.2B$36.8BAbbVie Inc. (approx. USD)
2024$56.3B$33.4BAbbVie Inc. (approx. USD)
2023$54.3B$28.2BAbbVie Inc. (approx. USD)
2022$58.1B$26.3BAbbVie Inc. (approx. USD)
2021$56.2B$26.0BAbbVie Inc. (approx. USD)

Business Model Breakdown

Overview: AbbVie Inc. vs Amgen Inc.

This in-depth comparison examines AbbVie Inc. and Amgen Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating Amgen Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and Amgen Inc. is widest.

On the headline numbers, annual revenue is $61.2B (FY2025) for AbbVie Inc. and $36.8B (FY2025) for Amgen Inc., while their respective market capitalizations stand at $465.8B and $228.2B. Both AbbVie Inc. and Amgen Inc. are headquartered in United States. Their local markets and applicable rules may still differ.

AbbVie Inc.: AbbVie became an independent public biopharmaceutical company in January 2013 after Abbott Laboratories separated its research-based pharmaceutical business. Humira initially dominated its portfolio. AbbVie has since added Pharmacyclics, Allergan, ImmunoGen, and Cerevel and now reports major portfolios in immunology, neuroscience, oncology, and aesthetics. The company is headquartered in North Chicago, Illinois.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

Business Models: How AbbVie Inc. and Amgen Inc. Make Money

AbbVie Inc. and Amgen Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and Amgen Inc..

AbbVie Inc. business model: AbbVie Inc. is a global biopharmaceutical research and development company that discovers, manufactures, and markets advanced medicines across immunology, oncology, neuroscience, and aesthetic medicine. Formed in 2013 as a spin-off from Abbott Laboratories, AbbVie built its initial commercial empire around Humira (adalimumab)—historically the world's best-selling biologic medicine. Today, AbbVie's business model is anchored by its next-generation immunology franchise: Skyrizi (risankizumab for plaque psoriasis, psoriatic arthritis, and Crohn's disease) and Rinvoq (upadacitinib for rheumatoid arthritis, ulcerative colitis, and atopic dermatitis). Through its landmark sixty-three-billion-dollar acquisition of Allergan, AbbVie operates a lucrative commercial aesthetics and therapeutic franchise led by Botox (Botox Cosmetic and Botox Therapeutic for migraine, spasticity) and the Juvederm dermal filler portfolio, alongside specialized oncology therapeutics like Venclexta and Imbruvica.

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

Competitive Advantage: AbbVie Inc. vs Amgen Inc.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of Amgen Inc..

AbbVie Inc. competitive advantage: AbbVie's durable competitive moat is built upon its world-class commercial execution in immunology, unmatched patent estate design, and the high-margin cash flow engine of the Allergan aesthetics portfolio. When facing the loss of exclusivity for Humira in the United States, AbbVie executed one of the most successful commercial pipeline replacements in biopharma history: developing Skyrizi and Rinvoq with superior clinical efficacy, securing favorable formulary placement with pharmacy benefit managers, and guiding them to combined annual revenues that surpass Humira's peak. In aesthetics, Botox operates with high consumer brand equity and medical practitioner loyalty; because cosmetic neurotoxin injections require physician skill and patient trust, Botox commands extraordinary pricing power and consumer cash-pay insulation from insurance reimbursement cuts.

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

Growth Strategy: Where AbbVie Inc. and Amgen Inc. Are Headed

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and Amgen Inc. each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuroscience programs, and Allergan added Botox, Vraylar, migraine products, eye care, and aesthetics.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

Financial Picture: AbbVie Inc. vs Amgen Inc.

A closer look at the financial trajectory of AbbVie Inc. and Amgen Inc. rounds out the comparison.

AbbVie Inc.: AbbVie reported $61.160 billion of FY2025 net revenue and $4.226 billion of net income. Skyrizi and Rinvoq generated $25.866 billion combined, while Humira declined to $4.540 billion after U.S. biosimilar entry. The 2020 Allergan acquisition added neuroscience and aesthetics revenue, and the 2024 ImmunoGen and Cerevel acquisitions added oncology and neuroscience assets. AbbVie is a dominant biopharmaceutical company, sustaining a massive market valuation often exceeding $250 billion, heavily driven by its blockbuster immunology and aesthetics portfolios.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025. Amgen Inc. is one of the world's largest independent biotechnology companies, holding a massive market valuation often exceeding $150 billion.

Company-Specific SWOT Notes

AbbVie Inc.

Strength

Skyrizi generated $17.562 billion and Rinvoq generated $8.304 billion in FY2025 global net revenue, or $25.866 billion combined, after U.S. Humira biosimilar entry.

Strength

AbbVie is no longer only an immunology company.

Weakness

Humira's decline shows the core weakness of the pharmaceutical model: even notable blockbusters eventually lose exclusivity.

Weakness

Even after diversification, AbbVie's earnings power is tied heavily to Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Humira.

Opportunity

Cerevel adds neuroscience pipeline depth, while ImmunoGen adds Elahere and antibody-drug conjugate expertise.

Threat

U.S. drug-pricing pressure remains a major threat.

Amgen Inc.

Strength

Amgen has been manufacturing large-molecule biologic drugs at commercial scale since 1989, longer than any other independent biotechnology company.

Strength

Amgen's revenue base spans inflammation, bone health, cardiovascular, oncology, and rare diseases, reducing dependence on any single therapeutic category.

Weakness

The US$27.8 billion Horizon acquisition was debt financed.

Weakness

Prolia and XGEVA share the denosumab molecule and generated US$6.50 billion of combined sales in fiscal 2025.

Opportunity

MariTide (maridebart cafraglutide) is in six Phase 3 MARITIME studies covering chronic weight management with and without Type 2 diabetes, cardiovascular outcomes, heart failure and obstructive sleep apnea.

Threat

The Inflation Reduction Act's Medicare negotiation provisions represent a structural threat to Amgen's long-term pricing power.

Factual Scorecard

CategoryResultWhy
Same-period Revenue ScaleAbbVie Inc.$61.2B (FY2025) versus $36.8B (FY2025); the higher figure is identified after approximate USD conversion.
Founded EarlierAmgen Inc.AbbVie Inc. was founded in 2013; Amgen Inc. was founded in 1980.
Verdict

Comparison Takeaway: AbbVie vs Amgen

AbbVie is the dominant specialty biopharma powerhouse, offering higher operating margins, a 3.5%+ dividend yield, and exceptionally strong commercial execution in replacing Humira with next-generation immunology leaders Skyrizi and Rinvoq. Amgen is a premier biotechnology compounder with deep multi-therapeutic breadth across rare diseases, oncology biosimilars, and a promising clinical pipeline in cardiometabolic and obesity therapies.

Methodology and sourcing reviewed by Swet Parvadiya. No date is shown unless this comparison has its own editorial review date.

Frequently Asked Questions: AbbVie vs Amgen

How do AbbVie and Amgen compare in annual revenue?

AbbVie generated $54.3 billion in revenue in 2023, nearly double Amgen's $28.2 billion. With Amgen's consolidation of Horizon Therapeutics, its annual revenue reached approximately $33.9 billion in 2024, closing the revenue gap.

Did Amgen develop a biosimilar to AbbVie's Humira?

Yes. Amgen developed Amjevita (adalimumab-atto), which was the first FDA-approved biosimilar to Humira. Amgen launched Amjevita in the United States in January 2023, initiating the commercial loss-of-exclusivity cycle for AbbVie's flagship product.

What is Amgen's MariTide drug and how does it compete?

MariTide is Amgen's investigational bispecific molecule targeting GLP-1 receptor agonism and GIP receptor antagonism. Early clinical trials showed substantial weight loss with once-monthly or less frequent dosing, positioning it as a potential major competitor to Eli Lilly's Zepbound and Novo Nordisk's Wegovy.

What was Amgen's largest acquisition in company history?

Amgen acquired Horizon Therapeutics for $27.8 billion in October 2023, gaining ownership of high-margin rare disease drugs including Tepezza (for thyroid eye disease), Krystexxa (for chronic refractory gout), and Uplizna (for neuromyelitis optica spectrum disorder).

How do AbbVie and Amgen compare in oncology commercial assets?

In oncology, AbbVie is anchored by hematologic cancer therapies Venclexta (BCL-2 inhibitor) and Imbruvica (BTK inhibitor), alongside its acquisition of ImmunoGen, which added targeted antibody-drug conjugate Elahere for platinum-resistant ovarian cancer. Amgen's oncology portfolio features Lumakras (KRAS G12C inhibitor for non-small cell lung cancer), Kyprolis for multiple myeloma, and Blincyto (bispecific T-cell engager for acute lymphoblastic leukemia).

Which company was founded first, AbbVie Inc. or Amgen Inc.?

Amgen Inc. was founded in 1980; AbbVie Inc. was founded in 2013.

What revenue did AbbVie Inc. and Amgen Inc. report?

AbbVie Inc. had $61.2B (FY2025), while Amgen Inc. had $36.8B (FY2025). These figures describe revenue scale; they do not by themselves determine an overall winner.

How do AbbVie Inc. and Amgen Inc. make money?

AbbVie Inc.: AbbVie Inc. is a global biopharmaceutical research and development company that discovers, manufactures, and markets advanced medicines across immunology, oncology, neuroscience, and aesthetic medicine. Amgen Inc.: Amgen operates a high-risk, high-reward biopharmaceutical business model.

Which is better, AbbVie Inc. or Amgen Inc.?

There is no evidence-based single winner. Compare AbbVie Inc. and Amgen Inc. on the same fiscal period and the metric relevant to the question, such as revenue, profitability, growth, product fit, or market value.

Sources & References

Quick Answer

AbbVie is the bigger company by revenue, but Amgen earned more profit in 2025. AbbVie reported $61.2 billion of revenue against Amgen's $36.8 billion, while Amgen's net income was $7.7 billion, about 1.8 times AbbVie's $4.2 billion. AbbVie was worth about twice as much on September 29, 2026: about $465.3 billion against $229.0 billion.

Verdict

AbbVie is the dominant specialty biopharma powerhouse, offering higher operating margins, a 3.5%+ dividend yield, and exceptionally strong commercial execution in replacing Humira with next-generation immunology leaders Skyrizi and Rinvoq. Amgen is a premier biotechnology compounder with deep multi-therapeutic breadth across rare diseases, oncology biosimilars, and a promising clinical pipeline in cardiometabolic and obesity therapies.

Cite This Page

Automatically generated citations for researchers.

APA Format

CorpDigest. (2026). AbbVie Inc. vs Amgen Inc. Comparison. from https://corpdigest.com/compare/abbvie-vs-amgen

MLA Format

CorpDigest. "AbbVie Inc. vs Amgen Inc. Comparison." CorpDigest, 2026, https://corpdigest.com/compare/abbvie-vs-amgen.

Chicago Format

CorpDigest. "AbbVie Inc. vs Amgen Inc. Comparison." CorpDigest. 2026. https://corpdigest.com/compare/abbvie-vs-amgen.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.